Compare EFSC & TRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EFSC | TRAX |
|---|---|---|
| Founded | 1988 | 2025 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.9B |
| IPO Year | 1996 | 2026 |
| Metric | EFSC | TRAX |
|---|---|---|
| Price | $62.55 | $50.31 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 12 |
| Target Price | $69.57 | ★ $75.17 |
| AVG Volume (30 Days) | 210.3K | ★ 776.1K |
| Earning Date | 10-21-2026 | 11-03-2026 |
| Dividend Yield | ★ 2.31% | N/A |
| EPS Growth | ★ 9.94 | N/A |
| EPS | ★ 3.54 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $3.10 | N/A |
| Revenue Next Year | $6.95 | N/A |
| P/E Ratio | $17.65 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $51.40 | $15.69 |
| 52 Week High | $68.73 | $54.78 |
| Indicator | EFSC | TRAX |
|---|---|---|
| Relative Strength Index (RSI) | 55.44 | 63.56 |
| Support Level | $61.82 | $35.11 |
| Resistance Level | $68.08 | N/A |
| Average True Range (ATR) | 1.24 | 3.30 |
| MACD | 0.08 | 0.57 |
| Stochastic Oscillator | 35.47 | 61.08 |
Enterprise Financial Services Corporation is a financial holding company. It offers banking and wealth management services to individuals and business customers located in Arizona, California, Florida, Kansas, Missouri, Nevada, and New Mexico, in addition to loan and deposit production offices throughout the United States. The company offers a broad range of business and personal banking services including wealth management services. Its Lending services include commercial and industrial, commercial real estate, real estate construction and development, residential real estate and consumer loans.
First Tracks Biotherapeutics Inc is a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases. Its clinical-stage pipeline includes rosnilimab, a selective pathogenic T cell depleter, for which it completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA), ANB033, a CD122 antagonist, in a Phase 1b trial for celiac disease (CeD) and eosinophilic esophagitis (EoE), and ANB101, a BDCA2 modulator, in a Phase 1a trial. The company operates in one reportable segment focused on research and development activities to deliver immunology therapeutics for autoimmune and inflammatory diseases.